These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23131091)

  • 1. Malfunction of subpectorally implanted cardiac resynchronization therapy defibrillators due to weakened header bond.
    Hayat SA; Kojodjojo P; Mason A; Benfield A; Wright I; Whinnett Z; Lim PB; Davies DW; Lefroy D; Peters NS; Kanagaratnam P
    J Cardiovasc Electrophysiol; 2013 Mar; 24(3):351-5. PubMed ID: 23131091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
    Alam MB; Munir MB; Rattan R; Flanigan S; Adelstein E; Jain S; Saba S
    Europace; 2014 Feb; 16(2):246-51. PubMed ID: 24099864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unprecedented cause of cardiac resynchronization with defibrillator (CRT-D) malfunction "A beheaded generator assembly".
    Prasitlumkum N; Ding K; Doyle K; Pai RG; Lo R
    J Cardiovasc Electrophysiol; 2022 Apr; 33(4):769-772. PubMed ID: 35118754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports.
    Alam MB; Munir MB; Rattan R; Adelstein E; Jain S; Saba S
    Europace; 2017 Mar; 19(3):421-424. PubMed ID: 27009183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.
    Lunati M; Proclemer A; Boriani G; Landolina M; Locati E; Rordorf R; Daleffe E; Ricci RP; Catanzariti D; Tomasi L; Gulizia M; Baccillieri MS; Molon G; Gasparini M;
    Europace; 2016 Sep; 18(9):1391-8. PubMed ID: 26826135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.
    Landolina M; Morani G; Curnis A; Vado A; D'Onofrio A; Bianchi V; Stabile G; Crosato M; Petracci B; Ceriotti C; Bontempi L; Morosato M; Ballari GP; Gasparini M
    Europace; 2017 Aug; 19(8):1349-1356. PubMed ID: 27702861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.
    Landolina M; Curnis A; Morani G; Vado A; Ammendola E; D'onofrio A; Stabile G; Crosato M; Petracci B; Ceriotti C; Bontempi L; Morosato M; Ballari GP; Gasparini M
    Europace; 2015 Aug; 17(8):1251-8. PubMed ID: 25976906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sprint Fidelis lead fractures in patients with cardiac resynchronization therapy devices: insight from the Resynchronization/Defibrillation for Ambulatory Heart Failure (RAFT) study.
    Parkash R; Thibault B; Sterns L; Sapp J; Krahn A; Talajic M; Luce M; Yetisir E; Theoret-Patrick P; Wells G; Tang A
    Circulation; 2012 Dec; 126(25):2928-34. PubMed ID: 23159551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pacing and sensing optimization of permanent His-bundle pacing in cardiac resynchronization therapy/implantable cardioverter defibrillators patients: value of integrated bipolar configuration.
    Su L; Xu L; Wu SJ; Huang WJ
    Europace; 2016 Sep; 18(9):1399-405. PubMed ID: 26581403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantation feasibility, procedure-related adverse events and lead performance during 1-year follow-up in patients undergoing triple-site cardiac resynchronization therapy: a substudy of TRUST CRT randomized trial.
    Lenarczyk R; Kowalski O; Sredniawa B; Pruszkowska-Skrzep P; Mazurek M; Jędrzejczyk-Patej E; Woźniak A; Pluta S; Głowacki J; Kalarus Z
    J Cardiovasc Electrophysiol; 2012 Nov; 23(11):1228-36. PubMed ID: 22651239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One Indication for an Extravascular Cardiac Resynchronization Therapy Defibrillator: Lessons from a Combination Therapy Case with Epicardial Cardiac Resynchronization Therapy and a Subcutaneous Implantable Cardioverter Defibrillator.
    Ishii N; Nakajima K; Kakuta T; Noda T; Fujita T; Kusano K
    Intern Med; 2021 Jun; 60(12):1877-1880. PubMed ID: 33518564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement of implantable cardioverter defibrillators and cardiac resynchronization therapy devices: results of the European Heart Rhythm Association survey.
    Tilz R; Boveda S; Deharo JC; Dobreanu D; Haugaa KH; Dagres N
    Europace; 2016 Jun; 18(6):945-9. PubMed ID: 27297231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upgrade from implantable cardioverter-defibrillator vs. de novo implantation of cardiac resynchronization therapy: long-term outcomes.
    Jędrzejczyk-Patej E; Mazurek M; Kotalczyk A; Kowalska W; Konieczny-Kozielska A; Kozielski J; Podolecki T; Szulik M; Sokal A; Kowalski O; Kalarus Z; Średniawa B; Lenarczyk R
    Europace; 2021 Jan; 23(1):113-122. PubMed ID: 33257952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT.
    Perkiomaki JS; Ruwald AC; Kutyifa V; Ruwald MH; Mcnitt S; Polonsky B; Goldstein RE; Haigney MC; Krone RJ; Zareba W; Moss AJ;
    Europace; 2015 Dec; 17(12):1816-22. PubMed ID: 26071234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projected longevities of cardiac implantable defibrillators: a retrospective analysis over the period 2007-17 and the impact of technological factors in determining longevity.
    Paton MF; Landolina M; Billuart JR; Field D; Sibley J; Witte K
    Europace; 2020 Jan; 22(1):149-155. PubMed ID: 31407793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA.
    Boriani G; Merino J; Wright DJ; Gadler F; Schaer B; Landolina M
    Europace; 2018 Dec; 20(12):1882-1897. PubMed ID: 29757390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amiodarone is associated with adverse outcomes in patients with sustained ventricular arrhythmias upgraded to cardiac resynchronization therapy-defibrillators.
    Adelstein EC; Althouse AD; Davis L; Schwartzman D; Bazaz R; Jain S; Wang N; Saba S
    J Cardiovasc Electrophysiol; 2019 Mar; 30(3):348-356. PubMed ID: 30575185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
    Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.